Samsung-PolyPeptide Cooling-Off Period Begins September 1, 2026; Formal Tender Offer Runs September 15 to October 12
The Samsung Biologics tender offer for PolyPeptide Group AG (announced July 20 at CHF 44.31 per share, CHF 1.46 billion / $1.8 billion) entered its 10 SIX Swiss Exchange trading-day cooling-off period Tuesday September 1, 2026 following the Monday August 31 publication of the formal tender offer prospectus by Samsung's Swiss subsidiary Samsung Peptide AG. The main offer period commences Tuesday September 15 and runs through October 12, 2026 at 4 p.m. Swiss time. Closing conditions include a 66⅔% minimum acceptance threshold plus customary regulatory approvals. Draupnir Holding B.V. (approximately 55.65% of PolyPeptide shares outstanding) has already committed to tender all of its shares. Transaction close is targeted for end of 2026, after which Samsung intends to squeeze out remaining minorities and delist PolyPeptide from SIX, integrating the Malmö, Limhamn, Strasbourg, Braine-l'Alleud, and Torrance sites into Samsung's Incheon multi-modality footprint alongside the existing monoclonal antibody and antibody-drug conjugate operations.